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effects within a clinical trial is limited to some extent: even aResponse to Karadag
We agree insofar with Ahmed Karadag, that isotonic saline
(IS) can have positive effects when applied as an adjunct
therapy for cleansing the upper airways from secretions and
crusts. Although a recent Cochrane Database Systemic Review
concludes that ‘included trials were too small and had too high
a risk of bias to be confident about the possible benefits of nasal
saline irrigation in acute upper respiratory tract infections’ [1],
we recommend this approach to our patients suffering from
rhinosinusitic symptoms for CF and other respiratory diseases.
Therapeutic nasal lavages are commonly applied rinsing 125 mL
of IS through each nasal side (resulting total volume 250 mL).
We do not doubt that such volumes have the potential to also
remove allergens and some pathogens together with inflamma-
tory mediators.
However, we deem it unreasonable to compare 5 drops of IS
applied every 4 h with the dornase alfa treatment applied within
our trial. There is evidence that nasal drops or sprays, nasal lavage,
and conventional aerosols inhaled through the nasal airways do
not reach the paranasal sinuses unless the ostia have previously
been widened to about 4 mm, as shown by Grobler et al. [2].
In contrast, in-vitro deposition studies presented in Fig. 1 of
our publication [3] showed that about 19% of the 2.5 mL of
dornase alfa or IS applied with pulsating aerosols reaches the
nasal cavity, 7.5% of which reaches the paranasal sinuses. In-vivo
studies affirmed that only pulsating aerosols are deposited within
maxillary and ethmoidal sinuses [4].
The issue is clearly addressed in the results and discussion of
our publication on sinonasal inhalation of dornase alfa. We
provided a detailed comparison of effects of recombinant dornase
alfa and IS (see Fig. 3): sinonasal vibrating inhalation of dornase
alfa improved the symptoms by amean of−7.14 SNOT-20 points
whereas IS reduced symptoms for only −1.27 points. Thus, IS
had only non-significant effects on sinonasal symptoms (see
Fig. 2). An improvement of ≥ 5 SNOT-20 points is considered
to be clinically relevant.
Nevertheless, the objection against IS as placebo is worth to be
discussed more profoundly under the following two issues:1. Which alternative comparators exist to assess the effects of
dornase alfa?
2. What is the general definition of a placebo and how should
this be applied to our trial comparing dornase alfa and IS?.
sevier B.V. Asugar tablet can influence the patients' organism and distilled
water as an agent-free solution has strong osmotic effects when
applied to living organisms or tissues.
Furthermore, blinding can be difficult e.g. if, not as in our trial,
dornase alfa as color- and smell less solution is applied. In former
times, the subjects' safety was not controlled as it is today: for the
assessment of the effectivity of, e.g., antibiotics, the drugs' carrier
solution was taken as a placebo. This could consist of isotonic or
half isotonic saline, together with additives like phenols as
stabilisators. Nowadays, such a combined placebo would need to
pass through a pharmacologic and toxicologic drug admission
processes before being admitted for a clinical trial. As a result,
solutions like IS are frequently used as a placebo. This leads to
the question about the definition of placebo.
(2) Unfortunately, there is no unified definition, but rather an
intriguing discussion about placebo effects making it a field of
research of its own. This is why we were guided by the European
Medicines Agency (CPMP/ICH/364/96): “In a placebo-controlled
trial, subjects are randomly assigned to a test treatment or to an
identical-appearing treatment that does not contain the test
drug”. Due to the absence of dornase alpha (test drug) and
equivalent physical characteristics, IS met the requirements for
the designation as placebo in our study.
Altogether, the use of a substance as placebo or control, which
by itself can have some positive effects on the studies' endpoints,
has the consequence that effects of the assessed drug must be
higher to achieve significant changes compared to the control
substance.
Karadag submitted a very similar Letter to the Editor of
‘Drug Design, Development and Therapy’. In this journal we
recently published a pilot trial on sinonasal inhalation with
tobramycin as vibrating aerosol [5], which also had IS as
a placebo. In our response (publication in process) we could
exclude relevant antibacterial effects of IS on the primary end-
point of this trial Pseudomonas aeruginosa colony counts in
diagnostic nasal lavage compared to the applied antibiotic [6].References
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